Alios Biopharma Inc. clinical trials

Acquired by Johnson & Johnson, Nov 7, 2014 · source ↗

The registry lists 21 studies whose lead sponsor is Alios Biopharma Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 4, 2025.

Studies

Recruiting first, then most recently updated. Showing 21 of 21. All Johnson & Johnson studies →

• A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial VirusCompletedNCT02673476Phase 2

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge ModelCompletedNCT02094365Phase 2

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted before Alios Biopharma Inc. became part of Johnson & Johnson

• A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872CompletedNCT02888327Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy ParticipantsCompletedNCT03285620Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy VolunteersTerminatedNCT03411421Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Study of ALS-008176 in Infants Hospitalized With RSVCompletedNCT02202356Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted before Alios Biopharma Inc. became part of Johnson & Johnson

• A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis BCompletedNCT03439488Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy VolunteersCompletedNCT02512562Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1CompletedNCT02339207Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and SimeprevirCompletedNCT02569710Phase 2

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CCompletedNCT01790100Phase 2

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted before Alios Biopharma Inc. became part of Johnson & Johnson

• First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis CTerminatedNCT02510248Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• Study of Single and Multiple Doses of ALS-008176 in Healthy VolunteersCompletedNCT01906164Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted before Alios Biopharma Inc. became part of Johnson & Johnson

• First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1CompletedNCT01590407Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted before Alios Biopharma Inc. became part of Johnson & Johnson

• A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176CompletedNCT02231671Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted before Alios Biopharma Inc. became part of Johnson & Johnson

• First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1TerminatedNCT01554085Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted before Alios Biopharma Inc. became part of Johnson & Johnson

• A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus InfectionTerminatedNCT03253471Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B SubjectsWithdrawnNCT03125213Phase 2

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy VolunteersTerminatedNCT03032536Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge StudyCompletedNCT02588521Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson

• A Study to Assess the PK of AL-794 Formulations in Healthy SubjectsCompletedNCT02877160Phase 1

  Sponsor listed in the registry: Alios Biopharma Inc. · First submitted after Alios Biopharma Inc. became part of Johnson & Johnson